An interventional study of Dual GIP/GLP-1 receptor agonist in Tirzepatide, Frozen Embryo Transfer and Obesity, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment
To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 1,510 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →RenJi Hospital is the lead sponsor of 550 studies on the registry; 247 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 16-week tirzepatide pretreatment prior to FET alongside lifestyle modification guidance, with a target weight loss of 10%-15% of total body weight.
Drug: Dual GIP/GLP-1 receptor agonist
Participants will receive lifestyle modification guidance and proceed to FET with no predefined weight-loss target.
16 weeks treatment
Also known as: Tirzepatide
This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.
Good birth outcome rate
good birth outcome is defined as live birth(s) at ≥37 weeks, with infant birth weight between 2500 and 4000g and without a major congenital anomaly.
Time frame: at delivery
Biochemical pregnancy rate
biochemical pregnancy is defined as serum beta-human chorionic gonadotropin (β-hCG) ≥10 mIU/ml.
Time frame: 12-17 days after frozen embryo transfer
Clinical pregnancy rate
clinical pregnancy is defined as the ultrasound confirmation of at least one intrauterine gestational sac.
Time frame: 28-35 days after frozen embryo transfer
Implantation rate
implantation rate is calculated as the number of gestational sacs by a transvaginal ultrasound scan/number of embryos transferred.
Time frame: 28-35 days after frozen embryo transfer
Pregnancy loss rate
pregnancy loss is defined as pregnancies that eventuate in a spontaneous abortion or therapeutic abortion that occurred throughout pregnancy.
Time frame: From the date of confirmation of pregnancy until the date of pregnancy loss, up to 9 months
Live birth rate
live birth is defined as the delivery of any neonate with signs of life at ≥ 28 weeks of gestation.
Time frame: at delivery
Gestational weight gain
maternal weight gain during pregnancy.
Time frame: at delivery
Incidences of obstetric and neonatal complications
including gestational diabetes mellitus, pre-eclampsia, placenta previa, placental abruption, congenital anomalies, postpartum hemorrhage, preterm birth, neonatal respiratory distress syndrome, neonatal jaundice, neonatal infection, neonatal death, etc.
Time frame: From the establishment of clinically recognized pregnancy until six weeks after delivery
Incidence of composite endpoint of obesity-related pregnancy complications
composite incidences of miscarriage, gestational diabetes mellitus, hypertensive disorders of pregnancy, and preterm birth.
Time frame: From the establishment of clinically recognized pregnancy until six weeks after delivery
Birth weight
birth weight of the newborn at delivery.
Time frame: at delivery
Incidence of congenital anomalies
congenital malformations or birth defects.
Time frame: From the establishment of clinically recognized pregnancy until six weeks after delivery
Plan to share: Yes — Deidentified participant data
Supporting information: Study protocol, Statistical analysis plan
Time frame: 1 year after publication
Access criteria: The data of this study are available on request from the corresponding author. Investigators requesting data will need to provide a written protocol with an analysis plan and sign a data-sharing/access agreement. Use of the data will require approval from a designated independent review committee.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide